Valuation
- Market cap
- 1,441,334,000
- Revenue TTM
- $1,300,000
- Net income TTM
- $-140,060,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -10,773.85%
- Debt to equity
- -3.33
Trading
- Volume
- 201,400
- Avg volume
- 297,594
- Day's range
- $96.07 – $100.13
- Shares out
- 14,718,000
- Stochastic %K
- 4%
- Beta
- 3.82
- Analysts
- Strong Sell
- Price target
- $266.67
Company profile
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candid...
Show more
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 795 4220
- Website
- https://inhibrx.com
- Address
- 11025 North Torrey Pines Road, Suite 140, La Jolla, United States
Latest news
No headlines yet.
